Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $212.0 million.

  • Arrowhead Pharmaceuticals' Change in Receivables rose 838184.0% to $212.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $266.5 million, marking a year-over-year increase of 1056052.0%. This contributed to the annual value of $57.0 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Change in Receivables of $212.0 million as of Q4 2025, which was up 838184.0% from $47.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Receivables registered a high of $212.0 million during Q4 2025, and its lowest value of -$68.2 million during Q2 2023.
  • Moreover, its 5-year median value for Change in Receivables was $1.2 million (2022), whereas its average is $16.3 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Change in Receivables plummeted by 996000.0% in 2021, and later surged by 838184.0% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Change in Receivables (Quarter) stood at -$10.1 million in 2021, then skyrocketed by 477.61% to $38.2 million in 2022, then crashed by 103.27% to -$1.2 million in 2023, then skyrocketed by 300.64% to $2.5 million in 2024, then surged by 8381.84% to $212.0 million in 2025.
  • Its last three reported values are $212.0 million in Q4 2025, $47.1 million for Q3 2025, and $7.5 million during Q2 2025.